US equities
|
MU
$903.70
▲+0.00%
META
$630.56
▲+0.00%
SNDK
$1,255.58
▲+0.00%
NVDA
$216.00
▲+0.00%
TSLA
$391.62
▲+0.00%
SPCX
$146.90
▲+0.00%
SKHY
$142.62
▲+0.00%
INTC
$90.47
▲+0.00%
MU
$903.70
▲+0.00%
META
$630.56
▲+0.00%
SNDK
$1,255.58
▲+0.00%
NVDA
$216.00
▲+0.00%
TSLA
$391.62
▲+0.00%
SPCX
$146.90
▲+0.00%
SKHY
$142.62
▲+0.00%
INTC
$90.47
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Pieris Pharmaceuticals, Inc. - Common Stock
(NQ:
PIRS
)
13.60
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pieris Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
Next >
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
November 20, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 07, 2024
From
Palvella Therapeutics
Via
GlobeNewswire
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...
From
Palvella Therapeutics
Via
GlobeNewswire
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 10, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
March 29, 2023
Via
ACCESSWIRE
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
September 03, 2024
From
Halper Sadeh LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders
August 17, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
August 16, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
July 24, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 02, 2022
Via
ACCESSWIRE
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
July 24, 2024
From
Halper Sadeh LLC
Via
Business Wire
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 24, 2024
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
April 19, 2024
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
March 27, 2024
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
August 17, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
July 18, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
June 21, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 02, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 22, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 21, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 04, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
May 02, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
April 17, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
March 24, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
January 10, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
November 23, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 09, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
November 01, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
October 26, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
